Loading clinical trials...
Loading clinical trials...
A Phase III Multicenter, Randomized Study With Lenalidomide Maintenance vs Observation After Induction Regimen Containing Rituximab Followed by High Dose Chemotherapy and ASCT as First Line Treatment in Adult Patients With Advanced Mantle Cell Lymphoma
Conditions
Interventions
Lenalidomide
Locations
53
Italy
UO Ematologia Ospedale Dell'Angelo
Mestre, VE, Italy
SC Ematologia A.O.SS. Biagio e Antonio e C. Arrigo
Alessandria, Italy
AORN San G.Moscati
Avellino, Italy
Centro di riferimento Oncologico - Oncologia Medica A
Aviano (PN), Italy
Istituto di Ematologia ed Oncologia Medica A. Seragnoli Policlinico S. Orsola
Bologna, Italy
Divisione di Ematologia e TMO, Ospedale di Bolzano
Bolzano, Italy
Start Date
May 1, 2010
Primary Completion Date
December 1, 2017
Completion Date
January 1, 2019
Last Updated
February 9, 2018
NCT06263491
NCT05529069
NCT05006716
NCT06026319
NCT03523975
NCT01804686
Lead Sponsor
Fondazione Italiana Linfomi - ETS
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions